BR9609327A - Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos - Google Patents

Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos

Info

Publication number
BR9609327A
BR9609327A BR9609327A BR9609327A BR9609327A BR 9609327 A BR9609327 A BR 9609327A BR 9609327 A BR9609327 A BR 9609327A BR 9609327 A BR9609327 A BR 9609327A BR 9609327 A BR9609327 A BR 9609327A
Authority
BR
Brazil
Prior art keywords
compounds
contain
preparation
pharmaceutical agents
oxazolidinone derivatives
Prior art date
Application number
BR9609327A
Other languages
English (en)
Inventor
Christos Tsaklakidis
Wolfgang Schaefer
Liesel Doerge
Walter-Gunar Freibe
Angelika Esswein
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of BR9609327A publication Critical patent/BR9609327A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR9609327A 1995-07-07 1996-07-04 Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos BR9609327A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19524765A DE19524765A1 (de) 1995-07-07 1995-07-07 Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1996/002939 WO1997003072A1 (de) 1995-07-07 1996-07-04 Neue oxazolidinonderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
BR9609327A true BR9609327A (pt) 1999-05-25

Family

ID=7766252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609327A BR9609327A (pt) 1995-07-07 1996-07-04 Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos

Country Status (19)

Country Link
US (1) US5972947A (pt)
EP (1) EP0839147A1 (pt)
JP (1) JPH11508904A (pt)
KR (1) KR19990028792A (pt)
CN (1) CN1195348A (pt)
AU (1) AU709208B2 (pt)
BR (1) BR9609327A (pt)
CA (1) CA2225411A1 (pt)
CZ (1) CZ288619B6 (pt)
DE (1) DE19524765A1 (pt)
HU (1) HUP9900348A3 (pt)
IL (1) IL122815A0 (pt)
NO (1) NO310194B1 (pt)
NZ (1) NZ313599A (pt)
PL (1) PL324436A1 (pt)
SK (1) SK298A3 (pt)
TW (1) TW332206B (pt)
WO (1) WO1997003072A1 (pt)
ZA (1) ZA965712B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250250A1 (en) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Novel oxazolidine derivatives, process for their production and medicaments containing them
AR012443A1 (es) * 1997-04-16 2000-10-18 Uriach & Cia Sa J Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos
AR013693A1 (es) * 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003095446A1 (fr) * 2002-05-09 2003-11-20 Mochida Pharmaceutical Co., Ltd. Procede de production de 1-(4-pyridyl)-4-piperidone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE602005018381D1 (de) * 2004-10-18 2010-01-28 Lilly Co Eli 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2823159C (en) 2005-10-04 2014-10-21 Bayer Intellectual Property Gmbh Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
DE102007018662A1 (de) 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
DE102007028318A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
EP2140866A1 (en) * 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
US9464062B2 (en) 2012-11-28 2016-10-11 Temple University—Of the Commonwealth System of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
EP3085701B1 (en) * 2013-12-20 2019-02-20 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China N, n' substituted piperidinamine compounds, and preparation method and usage thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9122016D0 (en) * 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds
EP0623120A1 (en) * 1992-01-21 1994-11-09 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
PL310889A1 (en) * 1993-03-29 1996-01-08 Zeneca Ltd Heterocyclic derivatives as inhibitors of thrombocytes aggregation
EP0623615B1 (de) * 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III

Also Published As

Publication number Publication date
CZ423397A3 (cs) 1998-03-18
IL122815A0 (en) 1998-08-16
NO980059L (no) 1998-01-06
CZ288619B6 (cs) 2001-08-15
EP0839147A1 (de) 1998-05-06
HUP9900348A3 (en) 2000-11-28
SK298A3 (en) 1998-05-06
NO980059D0 (no) 1998-01-06
US5972947A (en) 1999-10-26
JPH11508904A (ja) 1999-08-03
CA2225411A1 (en) 1997-01-30
ZA965712B (en) 1998-01-05
WO1997003072A1 (de) 1997-01-30
MX9800157A (es) 1998-03-29
PL324436A1 (en) 1998-05-25
HUP9900348A2 (hu) 1999-05-28
AU6611396A (en) 1997-02-10
CN1195348A (zh) 1998-10-07
KR19990028792A (ko) 1999-04-15
TW332206B (en) 1998-05-21
NZ313599A (en) 1999-10-28
NO310194B1 (no) 2001-06-05
AU709208B2 (en) 1999-08-26
DE19524765A1 (de) 1997-01-09

Similar Documents

Publication Publication Date Title
BR9609327A (pt) Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9504509A (pt) Composto processo para sua preparaçao e formulaçao farmaceûtica
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
FI973518A (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
BR9601028A (pt) Compostos processo para sua preparação processo para a produção de preparações farmacêuticas preparação farmacêutica medicamento e uso
BR9510360A (pt) Derivados de piperazina medicamentos contendo esses compostos sua aplicação e processo para sua preparação
BR9701673A (pt) Disposição para a aplicação de um líquido medicinal
NO981008D0 (no) Farmasöytisk formulering
BR9708014A (pt) Derivados de arilglicinamida processo para a preparação deles e composições farmacêuticas contendo estes compostos
BR9708004A (pt) PirimidoÚ5,4¾pirimidinas medicamentos contendo estes compostos seu emprego e processos para sua preparação
BR9602150A (pt) Compostos processo para sua preparação processo para a produção de uma formulação farmacêutica formulação farmacêutica e uso
BR9601275A (pt) Compostos processo para sua preparação medicamentos preparação farmacêutica processo para sua produção e uso
BR9607095A (pt) Composto composição farmacêutica e processos para fabricar e para administrar um composto
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
BR9610733A (pt) Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
PT956054E (pt) Processo para vaporizar e sobeaquecer um agente de esterilizacao e dispositivo para a sua realizacao
BR9607626A (pt) Novos compostos farmacéuticos de naftila
BR9600339A (pt) Compostos composições farmacêuticas processo para a preparação de um composto e uso dos mesmos
BR9611234A (pt) Composto formulação farmacêutica uso do composto e processos para tratamento de uma dor e para a preparação de compostos
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto

Legal Events

Date Code Title Description
TC Change of name
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law